Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.

Zamarin D, Giralt S, Landau H, Lendvai N, Lesokhin A, Chung D, Koehne G, Chimento D, Devlin SM, Riedel E, Bhutani M, Babu D, Hassoun H.

Bone Marrow Transplant. 2013 Mar;48(3):419-24. doi: 10.1038/bmt.2012.151. Epub 2012 Aug 13.

2.

Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.

Shin HJ, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.

Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14.

PMID:
24813053
3.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.

Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. Epub 2007 May 29.

4.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G.

J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
21730266
5.

Relapsed multiple myeloma: who benefits from salvage autografts?

Chow AW, Lee CH, Hiwase DK, To LB, Horvath N.

Intern Med J. 2013 Feb;43(2):156-61. doi: 10.1111/j.1445-5994.2012.02867.x.

PMID:
22757772
7.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.

Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27.

PMID:
23708704
8.

Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.

Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN.

Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):458-63. doi: 10.3816/CLML.2010.n.078.

9.

First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.

Naumann-Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD004626. doi: 10.1002/14651858.CD004626.pub3. Review.

10.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

PMID:
18178602
11.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

PMID:
15561686
12.

Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.

Karlin L, Arnulf B, Chevret S, Ades L, Robin M, De Latour RP, Malphettes M, Kabbara N, Asli B, Rocha V, Fermand JP, Socie G.

Bone Marrow Transplant. 2011 Feb;46(2):250-6. doi: 10.1038/bmt.2010.90. Epub 2010 Apr 19.

PMID:
20400980
13.

Impact of early relapse after auto-SCT for multiple myeloma.

Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Litzow MR, Gertz MA.

Bone Marrow Transplant. 2008 Sep;42(6):413-20. doi: 10.1038/bmt.2008.180. Epub 2008 Jun 30.

PMID:
18587435
14.

Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, Lehners N, Egerer G, Ho AD, Goldschmidt H, Neben K.

Cancer. 2013 Jul 1;119(13):2438-46. doi: 10.1002/cncr.28104. Epub 2013 Apr 10.

15.

Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.

Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K; Fukuoka Blood and Marrow Transplant Group (FBMTG).

Intern Med. 2013;52(1):63-70. Epub 2013 Jan 1.

16.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.

Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.

17.

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.

Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text.

PMID:
24948586
18.

Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.

Barley K, Tindle S, Bagiella E, Jagannath S, Chari A.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):541-5. doi: 10.1016/j.clml.2015.05.004. Epub 2015 Jun 6.

PMID:
26119495
19.

Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.

El-Cheikh J, Crocchiolo R, Furst S, Stoppa AM, Ladaique P, Faucher C, Calmels B, Lemarie C, De Colella JM, Granata A, Coso D, Bouabdallah R, Chabannon C, Blaise D.

Am J Hematol. 2013 May;88(5):370-4. doi: 10.1002/ajh.23412. Epub 2013 Mar 5.

20.

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.

Parrish C, Rahemtulla A, Cavet J, Pearce RM, Kirkland K, Lee J, Cook M, Wilson K, Cook G; Clinical Trials Committee of the British Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1330-4. doi: 10.1016/j.bbmt.2015.03.026. Epub 2015 Apr 3.

Supplemental Content

Support Center